SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2018

Commission File Number: 001-38205

ZAI LAB LIMITED

(Translation of registrant's name into English)

4560 Jinke Road, Bldg. 1, 4F, Pudong, Shanghai, China 201210
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Conference Participation

Zai Lab Limited (the "Company") will be conducting meetings with investors attending the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California beginning on January 8, 2018. As part of these meetings, the Company will deliver the slide presentation attached to this report as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized..

ZAI LAB LIMITED

By: /s/ Samantha Du
Name: Samantha Du
Title: Chief Executive Officer

Dated: January 8, 2018

EXHIBIT INDEX

Exhibit No.	Description
Exhibit 99.1	Zai Lab Limited presentation for 36th Annual J.P. Morgan Healthcare Conference

Exhibit 99.1

Disclaimer

This presentation includes forward-looking statements, beliefs or opinions, including statements with respect to our business, financial condition, results of operations and plans. These forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond our control and all of which are based on our management's current beliefs and expectations about future events. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "believe," "expects," "may," "will," "could," "should," "shall," "risk," "intends," "estimates," "aims," "plans," "predicts," "continues," "assumes," "positioned" or "anticipates" or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. Forward-looking statements may and often do differ materially from actual results. No assurance can be given that such future results will be achieved. Factors that may materially affect our results include, among other things, the scope, rate and progress of our clinical and preclinical trials and other research and development activities, anticipating timing of new clinical trials, our plans to commercialize our product candidates, the timing of, and ability to, obtain and maintain necessary regulatory approvals for our product candidates and those risks listed in our prospectus filed with the Securities and Exchange Commission on September 21, 2017 and in our filings with the Securities and Exchange Commission. Such forward-looking statements contained in this presentation speak only as of the date of this presentation. We expressly disclaim any obligation or undertaking to update any forward-looking statement contained in this presentation to reflect any change in our expectations or any change in events, conditions or circumstances on which such statements are based unless required to do so by applicable law.

You may get copies of our final prospectus and other Securities and Exchange Commission filings for free by visiting EDGAR on the Securities and Exchange Commission's website at http://www.sec.gov.

Zai Lab – A China-based global innovative biopharma company

We are

China-based global biopharma

*focusing on **oncology, autoimmune** & **infectious diseases***

Developing innovative therapeutics

to transform the lives of patients in China and worldwide

We have

Partnerships with

leading biopharma companies such as Tesaro, Paratek, BMS, GSK and Five Prime

Broad pipeline

4 late-stage assets with greater China rights & 3 assets with global rights

We are supported by

Experienced leaderships

extensive track record in R&D, licensing, regulatory & commercialization

Initial Public Offering

completed in Sep.2017, including leading global and China-based healthcare investors

Recent highlights and anticipated upcoming milestones

2017 highlights

- ✓ Exclusive license agreement with Paratek in Greater China
- ✓ $30M Series C Financing
- ✓ $172.5M US IPO on Nasdaq
- ✓ Dosing of first patient in Ph III registrational trial of ZL-2306 for Ovarian Cancer
- ✓ Exclusive license agreement with Five Prime Therapeutics in Greater China
- ✓ Market registration application submitted for HK and Macau for Niraparib
- ✓ FPA 144 China CTA for pivotal trial submitted
- ✓ ZL-2401 Category 1 status obtained and CTA for registration trial submitted

2018 key milestones

- ☐ Begin commercialization of ZL-2306 in Macau & HK
- ☐ Initiate first-line ovarian treatment study of ZL-2306 in H1 2018
- ☐ Initiate SCLC pivotal study of ZL-2306 in H1 2018
- ☐ Initiate gBRAC+ breast cancer study to start in H1 2018
- ☐ ZL-2306 PK study of Ovarian to read-out in H2 2018
- ☐ FAP144 global phase III trial China part to start in H2 2018
- ☐ ZL-2301 Phase II data readout in H2 2018
- ☐ ZL-3101 Phase II data readout in H2 2018, and initiate Phase III global trial

Pioneering as the gateway to China, we envision Zai to become a fully integrated global innovative biopharma company



Strong leadership team with experience and expertise in both China and globally

Samantha Du
Ph.D.
Founder, Chairman and CEO

Qi Liu
M.D., Ph.D.
Chief Medical Officer - Oncology

Harald Reinhart
M.D.
Chief Medical Officer - Autoimmune and Infectious Diseases

James Yan
M.D., Ph.D.
EVP and Head of Preclinical

Ning Xu
M.D.
EVP Head of Clinical and Regulatory

Bo Zhang
Ph.D.
Vice President Head of CMC

Minghui Chen
Vice President Government & Regulatory Affairs

Tom Feng
Vice President Finance

Jonathan Wang
Vice President Head of BD

Scientific advisory board

Richard Flavell
Ph.D., FRS

Neal Rosen
M.D., Ph.D.

Gwen Fyfe
M.D.

Established R&D and manufacturing capabilities, with commercial infrastructure under construction

Research and Development
Global and Local Know-how

Robust Product Pipeline

- ✓ Proven track records of drug development
- ✓ Established research and discovery capabilities

Manufacturing
Leverage Government Incentives

Manufacturing Facilities

- ✓ Small molecule commercial facility
- ✓ Large molecule pilot facility (anticipated launch in H1 2018)



Commercial Sales
Build Lean and Specialized Salesforce

Cost-effective Approach

- ✓ Building commercialization capabilities

Broad China and global product pipeline focusing on oncology, autoimmune and infectious diseases

Program	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3/ pivotal	Commercial rights	Partner
ZL-2306 Niraparib	*Ovarian Cancer (2nd line maintenance)*					China, HK, and Macau	TESARO
	Ovarian Cancer (1st line maintenance)						
	gBRAC Breast Cancer						
	Small cell lung cancer						
ZL-2401 Omadacycline	*ABSSSI*					China, HK, Macau & Taiwan	PARATEK
	CABP						
FPA144	*Gastric Cancer / GEJ*					China, HK, Macau, TW	FivePrime
ZL-2301 Brivanib	*HCC*					China, HK, and Macau	Bristol-Myers Squibb
ZL-3101 Fugan	*Eczema, Psoriasis*					Global	gsk
ZL-2302	*NSCLC*					Global	SANOFI
ZL-1101	*GVHD, SLE*					Global	ucb

zai Lab

Onc. Infectious Auto-immune

Zai Lab's oncology pipeline to address unmet medical needs for Chinese oncology patients

China and US comparison on cancer incidence

New Incidence (000's)



Source: *Cancer Facts & Figures 2015*, American Cancer Society; *Cancer Statistics in China, 2015*, A Cancer Journal for Clinicians.
Note: The data of both US and China are for year 2015. 1. The incidence numbers refer to women only.

Zai also committed to contribute for solving the rapidly rising problem of antibiotic resistance in China

China consumes ***half*** of the global antibiotics usage, which is over ***160K*** tons, ***48%*** are used in human

Anti-infectious is the ***largest*** therapeutic area in China pharma market

Over ***1 million pre-mature death*** due to MDR in China by 2050

Chinese government committed to develop ***innovative therapies*** to tackle the MDR problem by 2020

Resistance of common Gram-negative Bacteria in China



Source: "The global threat of antimicrobial resistance" Lord Jim Oneil, 2016; <National plan for controlling MDR , 2016~2020>

Recent CFDA reform initiatives encourage innovation

Reform initiatives announced by Chinese govt. in 2017

Accelerate the review and approval of new drug applications	***China Joins ICH***	***Encourage China to join early global simultaneous development***	***Conditional Approvals for Urgently Needed Drugs***
Improve clinical trial infrastructure to encourage innovation	***Enhance IP and Data protection for innovative drugs***	***No CPP required for China NDA submission***	***Compassionate Use of Investigational Drugs***

Details of the reform still being discussed

Source: China CFDA

Detailed updates of our progress

ZL-2306 (Niraparib) development progressing well

Achievements in 2017

- First-Patient-In for abbreviated ovarian pivotal trial in Sep.
- Recruitment on track
- HK registration submitted
- Protocol discussions with CFDA for SCLC and breast cancer pivotal trials

Plan for 2018

- First-line ovarian treatment study to start in H1 2018
- SCLC cancer pivotal study to start in H1 2018
- gBRAC+ Breast cancer study to start in H1 2018
- PK study of Ovarian to read-out in H2 2018
- Combo study with PD-1 and other therapies being planned

ZL-2306 : Expected to be the first local PARPi approved in China without biomarker test

Niraparib is favorably positioned in China amongst existing PARPs due to potential early market entry and best in class profile

	Zejula™ / Niraparib	Lynparza™ / Olaparib	BGB-290	Others
Product				
Developer	TESARO / zai Lab	AstraZeneca	BeiGene	Clovis: Rubraca™ Pfizer: Talazoparib Abbvie: Veliparib Hansoh:Fluzoparib Qingfeng:SC10914
Existing key China studies	All comer 2nd line ovarian cancer	gBRAC, 2nd / 3rd line, ovarian cancer	gBRAC, 3rd line ovarian cancer	Various
Global status	Approved	Approved	Phase I	Various stages
China status	Phase III in progress	NDA filed in Dec. 2017	Starting Phase II	IND not submitted or Phase I

Given the improving regulatory environment in China, we are actively discussing with CFDA to potentially accelerate the development progress of Niraparib

Source: Company filings, Evaluate Pharma, Broker research reports.
Note: gBRCAm indicates germline BRCA mutation. 1. Through acquisition of Medivation in Aug, 2016, Medivation acquired Talazoparib from BioMarin in 2015.

Key 2017 accomplishments and anticipated 2018 milestone of other pipeline programs

2401 (Omadacycline)

- CTA submitted in late 2017
- Category 1 status obtained
- Finalizing protocol with CFDA, expect first subject in 2H 2018 for the trial to enable approval

2301 (Brivanib)

- Phase II trial ongoing and recruitment well on track
- Data presentation in medical conference in H2 2018

3101 (Fugan)

- Phase II trial ongoing and recruitment well on track
- Phase II data readout in H2 2018
- Start global phase III trial application submission

FPA144

- China CTA for phase III trial submitted in Dec. 2017
- Planned phase III to start in H2 2018

Five Prime collaboration reinforces Zai's competitive advantage and strategic role in global drug development

Asset

- FPA 144 - Anti-FGFR2b antibody
- **Gastric and GEJ cancer**
- Global phase 3 planned to start in 2018
- **Strong proof of concept** data in heavily pretreated gastric cancer patient

Strategic value to Zai

- Address one of the **most significant unmet** needs for cancer patients in China
- China as important part of global pivotal trial, with **China PI as global co-PI**
- **Pioneering** the new cooperation and development model

FivePrime

zai Lab™

Deal structure

- Exclusive license agreement in **Greater China** and **global strategic development** collaboration
- Zai responsible for China portion of global phase 3 trial / patient enrollment
- FPRX receives milestones and royalties
- ZLAB receives low single digit royalty on WW sales

Next steps

- China CTA application for phase III was submitted by end of Dec. 2017
- Preparing for pre-IND meetings and clinical plan

Simultaneously accelerating efforts to enhance integrated capabilities

Commercial

Establish commercial organization in HK, Macau and mainland China

To prepare for launch readiness, incl. market access strategy, pricing, etc.

Licensing & partnership

Continue licensing in quality assets

Establish broader partnerships

Discovery

Continue building up discovery platform

Expected to deliver two candidates

Financial overview

Cash and Cash Equivalents	~$240M cash at hand post IPO (pro-forma Sep. 2017), sufficient cash runway until at least end of 2019
Headcount	~100 headcount as of today; total 200+ headcount planned by end of 2018

Our 2020 vision : A leading China-based global innovative biopharma company



2+ products on market	3+ programs close to registration	Multiple programs in research & development

Thank You

www.zailaboratory.com